ACON

Aclarion Inc

ACON, USA

Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The company also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and data transfer products, including AMBRA Healthcare, an imaging data transfer platform and NOCIWEB, a custom developed web-interface. In addition, it offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

https://www.aclarion.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ACON
stock
ACON

Aclarion, Inc. (NASDAQ:ACON) Short Interest Update Defense World

Read more →
ACON
stock
ACON

How (ACON) Movements Inform Risk Allocation Models Stock Traders Daily

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$22

Analyst Picks

Strong Buy

1

Buy

0

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.18

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-13.65 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-12.93 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-6,164.55 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.06

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.82% of the total shares of Aclarion Inc

1.

UBS Group AG

(0.2969%)

since

2025/06/30

2.

Vanguard Institutional Extnd Mkt Idx Tr

(0.2935%)

since

2025/07/31

3.

Fidelity Extended Market Index

(0.1679%)

since

2025/07/31

4.

Spartan Total Market Index Pool G

(0.0489%)

since

2025/07/31

5.

Tower Research Capital LLC

(0.0129%)

since

2025/06/30

6.

Bank of America Corp

(0.0014%)

since

2025/06/30

7.

CLEAR STREET LLC.

(0.0005%)

since

2025/06/30

8.

State St US Extended Mkt Indx NL Cl C

(0.0002%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-2.93

EPS Estimate

-0.17

EPS Difference

-2.76

Surprise Percent

-1623.5294%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(6.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(2)
Net Net
Strong Net-Net(8)
Quality
Low Quality Business(2.5)
Value
Undervalued(6.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.